DIABINESE® (chlorpropamide), is an oral blood-glucose-lowering drug of the sulfonylurea class.
DIABINESE is indicated as an adjunct to diet to lower the blood glucose in patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet alone.
In initiating treatment for non-insulin-dependent diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified and corrective measures taken where possible.
If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of DIABINESE must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone may be transient, thus requiring only short-term administration of DIABINESE.
During maintenance programs, DIABINESE should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgments should be based on regular clinical and laboratory evaluations.
In considering the use of DIABINESE in asymptomatic patients, it should be recognized that controlling the blood glucose in non-insulin-dependent diabetes, has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes.
Published Studies Related to Diabinese (Chlorpropamide)
The influence of lamivudine, stavudine and nevirapine on the pharmacokinetics of chlorpropamide in human subjects. [2008.07]
Diabetic patients tend to be prone to infections, and multiple drug therapy cannot be ruled out in the management of diabetes. The effect of three routinely prescribed antiretroviral (ARV) drugs on the pharmacokinetic profile of an antidiabetic drug, chlorpropamide, was investigated in 18 human subjects, who had recently been diagnosed positive for human immunodeficiency virus (HIV) infection...
Comparative bioavailability study with two chlorpropamide tablet formulations in healthy volunteers. 
OBJECTIVE: The aim of this study was the assessment of the bioequivalence of two formulations (250 mg tablet) of chlorpropamide (CAS 94-20-2) in 36 healthy volunteers of both sexes... CONCLUSION: Since the 90 % CI for AUC(0-72h), AUC(0-inf) and C(max) ratios were within the 80-125%interval proposed by the US FDA, it was concluded that chlorpropamide 250 mg tablet (test formulation) was bioequivalent to the reference 250 mg tablet for of both the rate and extent of absorption.
Chlorpropamide treatment restores the reduced carrageenan-induced paw edema and pleural exudate volume in diabetic rats. [2008.09]
CONCLUSION: Chlorpropamide treatment by restoring beta-cell function, reducing blood sugar levels, and improving glucose tolerance might be contributing to the correction of the reduced inflammatory response tested as paw edema and pleural exudate in n-STZ diabetic rats.
Effect of Nigerian meals on the pharmacokinetics of chlorpropamide in type II diabetic patients. [2008.01]
Food-drug interactions are best evaluated on an individual drug basis, in a group of subjects in a population at risk. This is due to their complex nature, which is a function of type and size of meal, the physical and chemical form of the drug and the time lapse between food intake and drug administration...
Kinetic analysis of chlorpropamide dissolution from solid dispersions. [2007.01]
Solid dispersions (SDs) of chlorpropamide were prepared by the solvent deposition technique using two grades of microcrystalline cellulose as carrier materials with different ratios of drug to carrier. The dissolution rate of chlorpropmide from the SDs was carried out at two physiological pH values of 1.1 and 7.25 simulating gastric and intestinal environments...
Clinical Trials Related to Diabinese (Chlorpropamide)
Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus [Completed]
OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II
(AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by
directing the production of an abnormal preprohormone.
II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys
magnocellular neurons because it cannot be folded and processed efficiently.
Page last updated: 2009-02-08